Government Relations

About Us

Government Relations


Vice President Joe Biden visits Fred Hutch

Vice President Joe Biden visits Fred Hutch on his "Cancer Moonshot" listening tour March 21, 2016.

Photo By Robert Hood / Fred Hutch News Service

The Hutch is a global leader in generating new scientific discoveries and translating them into effective medical practices and cures

At Fred Hutch, interdisciplinary teams of world-renowned scientists work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit of, and passion for, health knowledge and hope to their work and the world.

Together, our researchers are discovering new ways to detect cancers earlier, when cure rates are highest; developing effective treatments with fewer side effects; and learning how to prevent cancers from growing in the first place.

We are here to help

The Government Relations team at Fred Hutch stands ready to serve all local, regional, state, federal and international partners in advancing biomedical discovery and cure.

For more information about our work, to speak with our experts or tour our Seattle campus on South Lake Union, please contact  

Fast Facts

Hutch Overview

  • 3 Nobel Laureates
  • 40+ years of research
  • global reach in 70+ countries
  • 250+ clinical trials
  • 1 million+ bone marrow transplants worldwide
  • 1 million+ participants in Hutch studies

Latest News

Penn panel aptly dubbed 'A Formidable Foe: Cancer in the 21st Century'

Fred Hutch President and Director Dr. Gary Gilliland responds to question at press conference in response to the proposed budget cuts to National Institutes of Health (NIH).

Photo by Bo Jungmayer

Statement from Dr. Gary Gilliland on the impact of President Trump’s budget proposal

Fred Hutch’s first advocacy priority is federal funding for science. At Fred Hutch, federally -sponsored research revenues comprise about 85 percent of our total sponsored funding. We are the recipient of more NIH grants than any other cancer research center in the country. We are at an inflection point in our efforts to develop cures for cancer and related diseases. In that context, the proposed cuts are indefensible and would severely impede our progress. Patient lives are at stake.

Read more

Science Snapshots


Empowering the Immune System

Fred Hutch is at the forefront of a fundamental shift in the way cancer is treated and cured. Our researchers have discovered new ways to empower a patient’s own immune system to do what it does naturally — fight disease — with far fewer side effects than conventional cancer treatments.

Our Nobel Prize-winning work on bone marrow transplantation provided the first definitive and reproducible example of the human immune system's power to cure cancer. Today, we continue to lead this revolutionary field, called immunotherapy.  

We've already used immunotherapy to boost survival rates for patients with leukemia and other blood cancers.

Precision Oncology

Turning Scientific Advances into Precise Treatments

Fred Hutch's goal is to rapidly translate recent, stunning advances in molecular biology and computational science into the most precise treatment options — to find the right drug for the right patient at the right time. Through precision oncology, the Hutch aims not only to extend and save lives, but to lower the cost of cancer care.

Our scientists sense an historical moment. We can quickly parse whole human genomes, generating individual sequences for less than it costs to store them. And we can learn, in a cost-effective way, how and why what drugs work for which patients. Fred Hutch, with a legacy of lifesaving advances in cancer research and care, is perfectly positioned to take advantage of the Seattle area’s innate strengths in big data, digital technology and the life sciences.

Bridging Research and Practice

Reducing the Economic and Human Burden of Cancer

Hutchinson Institute for Cancer Outcomes Research (HICOR) develops and applies innovative scientific methods in health economic, clinical and public health research and data science to enhance value in cancer care and improve outcomes for patients. 

HICOR's approach is built on the concepts of stakeholder engagement, bringing together patients and patient advocacy groups, health insurers, large regional employers, public health and clinical researchers, technology and drug developers, oncologists, primary care physicians and health care delivery systems.

Through this consortium, HICOR has outlined value measures as guidling frameworks.  

HIV Vaccine

Best Long-Term Hope For Ending AIDS

The HIV Vaccine Trials Network (HVTN) goal is to developi a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.  It is the world’s largest publicly funded multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV/AIDS.

The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Headquartered at the Fred Hutch, the network includes over 30 sites on five continents

To date, the HVTN  has conducted the majority of the published, presented, or ongoing clinical trials of preventive HIV vaccines worldwide.